ZVRA

Companies
NASDAQ
Zevra Therapeutics Inc.
Health Care
Price Chart
Overview

About ZVRA

kempharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (nces) to treat serious medical conditions through its proprietary and broadly applicable ligand activated therapy (lat) approach. the company utilizes its lat technology to generate improved prodrug versions of fda approved drugs in the high needs areas of pain, adhd and other cns diseases.

Market Cap
$194.6M
Volume
6.4M
Avg. Volume
5.2M
P/E Ratio
-22.205128
Dividend Yield
0.00%
Employees
52.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
0.81
Moderate Correlation
Volatility
High (0.58)
Relative to market

Macro Factor Sensitivities

Interest Rates
Medium Sensitivity
Inflation
Low Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for ZVRA.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, ZVRA shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$194.6M
Volume6.4M
P/E Ratio-22.21
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 14, 2025
Related Securities

PortfolioPilot Analysis

Get AI-powered insights on how ZVRA fits into your investment strategy and portfolio diversification.

Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025